keyword
MENU ▼
Read by QxMD icon Read
search

Emtricitabine

keyword
https://www.readbyqxmd.com/read/29781878/hiv-1-proviral-sequence-and-treatment-outcome-of-virologically-suppressed-patients-switching-to-coformulated-elvitegravir-cobicistat-emtricitabine-tenofovir-disoproxil-fumarate
#1
Kristen Andreatta, Silvia Chang, Ross Martin, Rima Kulkarni, Martin Daeumer, Alexander Thielen, Michael D Miller, Kirsten L White
No abstract text is available yet for this article.
May 16, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29777425/the-use-of-hiv-post-exposure-prophylaxis-in-forensic-medicine-following-incidents-of-sexual-violence-in-hamburg-germany-a-retrospective-study
#2
Julia Ebert, Jan Peter Sperhake, Olaf Degen, Ann Sophie Schröder
In Hamburg, Germany, the initiation of HIV post-exposure prophylaxis (HIV PEP) in cases of sexual violence is often carried out by forensic medical specialists (FMS) using the city's unique Hamburg Model. FMS-provided three-day HIV PEP starter packs include a combination of raltegravir and emtricitabine/tenofovir. This study aimed to investigate the practice of offering HIV PEP, reasons for discontinuing treatment, patient compliance, and whether or not potential perpetrators were tested for HIV. We conducted a retrospective study of forensic clinical examinations carried out by the Hamburg Department of Legal Medicine following incidents of sexual violence from 2009 to 2016...
May 18, 2018: Forensic Science, Medicine, and Pathology
https://www.readbyqxmd.com/read/29771790/patterns-and-correlates-of-participant-retention-in-a-multi-city-pre-exposure-prophylaxis-demonstration-project
#3
Susanne Doblecki-Lewis, Albert Y Liu, Daniel J Feaster, Stephanie E Cohen, Richard Elion, Oliver Bacon, Megan Coleman, Gabriel Cardenas, Michael A Kolber
BACKGROUND: Safe and effective use of pre-exposure prophylaxis (PrEP) depends on retention in care after initial engagement. SETTING: The United States PrEP Demonstration Project offered daily oral tenofovir/emtricitabine to participants in San Francisco, Miami, and Washington, D.C. for 48 weeks from 2012-2014. METHODS: Demo Project participants' patterns of retention were assigned to one of three categories: early loss to follow-up (ELTF) within the first 12 weeks of the study, retention throughout the study, or intermittent retention in which missed or delayed visits resulted in gaps in medication availability...
May 3, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29771789/raltegravir-1200-mg-once-daily-vs-400-mg-twice-daily-with-emtricitabine-and-tenofovir-disoproxil-fumarate-for-previously-untreated-hiv-1-infection-week-96-results-from-oncemrk-a-randomized-double-blind-non-inferiority-trial
#4
Pedro Cahn, Paul E Sax, Kathleen Squires, Jean-Michel Molina, Winai Ratanasuwan, Mohammed Rassool, Mark Bloch, Xia Xu, Yan Zhou, Brenda Homony, Deborah Hepler, Hedy Teppler, George J Hanna, Bach-Yen Nguyen, Wayne Greaves
BACKGROUND: Raltegravir 1200mg (2x600mg tablets) once daily (QD) demonstrated non-inferior efficacy and similar safety to raltegravir 400mg BID at Week 48 of the ONCEMRK trial. Here we report the Week 96 results from this study. METHODS: ONCEMRK is a phase 3, multicenter, double-blind, non-inferiority trial comparing raltegravir 1200mg QD to raltegravir 400mg BID in treatment-naïve HIV-1-infected adults. Participants were assigned (2:1) to raltegravir 2x600mg QD or 400mg BID, both with emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) for 96 weeks...
May 3, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29770060/setting-the-stage-for-expanding-hiv-pre-exposure-prophylaxis-use-in-canada
#5
EDITORIAL
M Hull, Dhs Tan
Human immunodeficiency virus (HIV) infection continues to disproportionately affect vulnerable populations in Canada; particularly men who have sex with men (MSM). Novel HIV prevention strategies have recently expanded from the use of non-occupational post-exposure prophylaxis (nPEP) after high risk exposures to the use of pre-exposure prophylaxis (PrEP) in which individuals reduce risk of HIV infection through use of combination antiretrovirals taken prior to risk exposure. With approval of tenofovir/emtricitabine (TDF/FTC) for use as PrEP only in early 2016, and with limited public funding to date, uptake in Canada is in its preliminary stages...
December 7, 2017: Canada Communicable Disease Report, Relevé des Maladies Transmissibles Au Canada
https://www.readbyqxmd.com/read/29767638/pre-exposure-prophylaxis-with-tenofovir-disoproxil-fumarate-emtricitabine-and-kidney-tubular-dysfunction-in-hiv-uninfected-individuals
#6
Vasantha Jotwani, Rebecca Scherzer, David V Glidden, Megha Mehrotra, Patricia Defechereux, Albert Liu, Monica Gandhi, Michael Bennett, Steven G Coca, Chirag R Parikh, Robert M Grant, Michael G Shlipak
BACKGROUND: Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is becoming increasingly adopted for HIV prevention. Tenofovir can cause proximal tubular damage and chronic kidney disease in HIV-infected persons, but little is known regarding its nephrotoxic potential among HIV-uninfected persons. In this study, we evaluated the effects of PrEP on urine levels of the following: α1-microglobulin (α1m), a marker of impaired tubular reabsorption; albuminuria, a measure of glomerular injury; and total proteinuria...
June 1, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29767543/efficacy-of-single-tablet-darunavir-cobicistat-emtricitabine-and-tenofovir-alafenamide-in-the-treatment-of-hiv-1
#7
Eugènia Negredo, Bonaventura Clotet
HIV eradication is not feasible and lifelong treatment is warranted to manage HIV infection. In this scenario, the advent of single-tablet, once-daily, fixed-dose co-formulations is important for reducing pill burden and maximize long-term drug adherence. Cobicistat-boosted darunavir along with emtricitabine and tenofovir alafenamide co-formulation (DRV/c/FTC/TAF or the trade name Symtuza®) is the first marketed protease inhibitor-based fixed-dose combination regimen for the treatment of HIV infection. It was approved in late 2017 by the European Medical Agency both for naïve patients and treatment-experienced patients with viral suppression...
May 16, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29759422/executive-summary-of-the-gesida-national-aids-plan-consensus-document-on-antiretroviral-therapy-in-adults-infected-by-the-human-immunodeficiency-virus-updated-january-2018
#8
(no author information available yet)
This update to the document on antiretroviral therapy (ART) in adults, which has been prepared jointly by GeSIDA and the Spanish National AIDS Plan for the last two decades, supersedes the document published in 2017.1 The update provides physicians treating HIV-1-infected adults with evidence-based recommendations to guide their therapeutic decisions. The main difference with respect to the previous document concerns recommended initial ART regimens, only three of which are maintained as preferential. All three include dolutegravir or raltegravir, together with emtricitabine/tenofovir alafenamide or abacavir/lamivudine...
May 11, 2018: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/29746294/a-maintenance-three-day-per-week-schedule-with-the-single-tablet-regimen-efavirenz-emtricitabine-tenofovir-disoproxil-fumarate-is-effective-and-decreases-sub-clinical-toxicity-the-a-tri-week-pilot-trial
#9
Jhon Rojas, Jose L Blanco, Sonsoles Sanchez-Palomino, Maria A Marcos, Alberto C Guardo, Ana Gonzalez-Cordon, Montserrat Lonca, Amparo Tricas, Ana Rodriguez, Anabel Romero, Jose M Miro, Josep Mallolas, Jose M Gatell, Montserrat Plana, Esteban Martinez
BACKGROUND: Antiretroviral drugs contained in single tablet Atripla® have pharmacokinetic properties that could allow for longer than once-daily (OD) dosing. We hypothesized that simplifying Atripla® OD to 3-day per week would be feasible, able to maintain viral suppression and less toxic. METHODS: Virologically suppressed (≥2 years) HIV+ adults on Atripla® OD, CD4 >350/mm at inclusion, and no prior documented virological failure or evidence of resistance mutations to efavirenz, tenofovir, or emtricitabine were randomized to maintain their OD regimen or to reduce it to 3 days (Mondays, Wednesdays, and Fridays) a week (3W)...
May 9, 2018: AIDS
https://www.readbyqxmd.com/read/29746268/bictegravir
#10
Vincenzo Spagnuolo, Antonella Castagna, Adriano Lazzarin
PURPOSE OF REVIEW: In this review, we will highlight and discuss the recent efficacy and safety data of bictegravir (BIC), a novel second-generation integrase strand transfer inhibitor (INSTI) that has been recently approved, in coformulation with emtricitabine and tenofovir alafenamide (B/F/TAF), for the treatment of HIV-1 infection in antiretroviral naïve subjects and in those with suppressed viremia. RECENT FINDINGS: Preclinical data showed that BIC has a genetic barrier that is higher than that of raltegravir and elvitegravir but is similar to that of dolutegravir (DTG), with retained activity in vitro against isolates containing substitutions associated with resistance against other INSTIs...
May 4, 2018: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/29745457/subclinical-cardiovascular-disease-in-patients-starting-contemporary-protease-inhibitors
#11
A González-Cordón, M Doménech, M Camafort, M Martínez-Rebollar, B Torres, M Laguno, J Rojas, M Loncà, J L Blanco, J Mallolas, J M Gatell, E de Lazzari, E Martínez
OBJECTIVES: The aim of the study was to assess changes in and factors associated with anatomical [carotid artery intima-media thickness (CIMT)] and functional (arterial stiffness) markers of subclinical cardiovascular disease progression in antiretroviral-naïve patients starting triple combination antiretroviral therapy containing contemporary protease inhibitors. METHODS: This was a planned substudy of the ATADAR (Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients) clinical trial (ClinicalTrials...
May 10, 2018: HIV Medicine
https://www.readbyqxmd.com/read/29736816/pre-exposure-prophylaxis-for-hiv-infection-in-the-older-patient-what-can-be-recommended
#12
Iacopo Franconi, Giovanni Guaraldi
Over the past 15 years, a significant increase in new HIV/AIDS diagnoses has been observed in the elderly population. This new epidemiological shift has been attributed to a longer sex life, lifestyle and changes in sexual behavior, poor sexual health education, and misconceptions about the absence of sexually transmitted disease in later life. Although many biomedical and behavioral interventions have proven useful to prevent sexually transmitted infections and HIV, pre-exposure prophylaxis (PrEP) has been shown to be the most successful biomedical intervention to prevent HIV in high-risk individuals...
May 8, 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29727296/croi-2018-advances-in-antiretroviral-therapy
#13
Hong-Van Tieu, Barbara S Taylor, Joyce Jones, Timothy J Wilkin
The 2018 Conference on Retroviruses and Opportunistic Infections (CROI) showcased exciting data on new investigational agents including MK-8591 and tri-specific antibody targeting 3 highly conserved epitopes on HIV-1 in a single antibody. Clinical trials of initial antiretroviral therapy (ART) and switch studies involving bictegravir/emtricitabine/tenofovir alafenamide were presented. Intensification of initial ART with integrase strand transfer inhibitors did not increase the risk of immune reconstitution inflammatory syndrome...
May 2018: Topics in Antiviral Medicine
https://www.readbyqxmd.com/read/29718247/emerging-resistance-mutations-in-pi-naive-patients-failing-an-atazanavir-based-regimen-anrs-multicentre-observational-study
#14
S Lambert-Niclot, M Grude, M L Chaix, C Charpentier, S Reigadas, H Le Guillou-Guillemette, A Rodallec, C Amiel, A Maillard, J Dufayard, T Mourez, A Mirand, J Guinard, B Montes, S Vallet, A G Marcelin, D Descamps, P Flandre, C Delaugerre, L Morand-Joubert
Background: Atazanavir is a PI widely used as a third agent in combination ART. We aimed to determine the prevalence and the patterns of resistance in PI-naive patients failing on an atazanavir-based regimen. Methods: We analysed patients failing on an atazanavir-containing regimen used as a first line of PI therapy. We compared the sequences of reverse transcriptase and protease before the introduction of atazanavir and at failure [two consecutive viral loads (VLs) >50 copies/mL]...
April 27, 2018: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29714167/virological-and-immunological-responses-to-raltegravir-and-dolutegravir-in-the-gut-associated-lymphoid-tissue-of-hiv-infected-men-and-women
#15
Michael D Weber, Elizabeth Andrews, Heather A Prince, Craig Sykes, Elias P Rosen, Camden Bay, Nicholas J Shaheen, Ryan D Madanick, Evan S Dellon, Kristina De Paris, Julie Ae Nelson, Cynthia L Gay, Angela Dm Kashuba
BACKGROUND: Raltegravir (RTG) and dolutegravir (DTG) have different pharmacokinetic patterns in the gastrointestinal tract. To determine if this results in pharmacodynamic differences, we compared HIV RNA, HIV DNA, and immunological markers in gut-associated lymphoid tissue (GALT) of HIV-infected participants receiving RTG or DTG with tenofovir+emtricitabine (TDF/FTC). METHODS: GALT specimens from the terminal ileum, splenic flexure, and rectum were obtained by colonoscopy at a single time point in 20 adults treated with RTG (n=10) or DTG (n=10) with HIV RNA <50 copies/mL...
May 1, 2018: Antiviral Therapy
https://www.readbyqxmd.com/read/29713838/acceptability-of-antiretroviral-pre-exposure-prophylaxis-from-a-cohort-of-sexually-experienced-young-transgender-women-in-two-u-s-cities
#16
Arjee J Restar, Lisa Kuhns, Sari L Reisner, Adedotun Ogunbajo, Robert Garofalo, Matthew J Mimiaga
Emtricitabine/tenofovir disoproxil fumarate as pre-exposure prophylaxis (PrEP) can prevent HIV infection among at-risk individuals, including young transgender women (YTW). We used baseline data from 230 HIV-uninfected YTW (ages 16-29 years) who were enrolled in Project LifeSkills during 2012-2015. We examined factors associated with perceived acceptability of PrEP use (mean score = 23.4, range 10.0-30.0). Participants were largely transgender women of color (67%) and had a mean age of 23 years (SD = 3...
April 30, 2018: AIDS and Behavior
https://www.readbyqxmd.com/read/29709783/development-and-validation-of-an-lc-ms-ms-assay-for-tenofovir-and-tenofovir-alafenamide-in-human-plasma-and-cerebrospinal-fluid
#17
Andrew J Ocque, Colleen E Hagler, Gene D Morse, Scott L Letendre, Qing Ma
A liquid chromatography with triple quadrupole mass spectrometry method was developed and validated for the determination of tenofovir and tenofovir alafenamide concentrations in human plasma and cerebrospinal fluid. Tenofovir and tenofovir alafenamide were extracted from matrix by solid phase extraction. The dried extraction eluents were dissolved in water for LC-MS/MS analysis. Separation was achieved with a Phenomenex Synergi 4 μm Polar-RP 80A column (50 × 2 mm) with a gradient elution of 0.1% formic acid in water and acetonitrile...
April 23, 2018: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29700852/lc-ms-ms-method-for-the-simultaneous-determination-of-tenofovir-emtricitabine-elvitegravir-and-rilpivirine-in-dried-blood-spots
#18
Pavan Kumar Prathipati, Subhra Mandal, Christopher J Destache
A simple, short, and rugged LC-MS/MS method for the simultaneous determination of tenofovir, emtricitabine, elvitegravir and rilpivirine was developed and validated. Dried blood spots were prepared with 25 μL of spiked whole blood. A 3 mm punch was extracted with methanol containing labeled internal standards. Ten microliter was injected into LC-MS/MS using isocratic mobile phase composed of 0.1% formic acid in water and 0.1% formic acid in acetonitrile (45: 55 v/v) at a flow rate of 0.25 mL/min. The method was validated in the range of 10 to 2000 ng/mL for all four analytes...
April 26, 2018: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/29694825/birth-outcomes-for-pregnant-women-with-hiv-using-tenofovir-emtricitabine
#19
COMPARATIVE STUDY
Kathryn Rough, George R Seage, Paige L Williams, Sonia Hernandez-Diaz, Yanling Huo, Ellen G Chadwick, Judith S Currier, Risa M Hoffman, Emily Barr, David E Shapiro, Kunjal Patel
BACKGROUND: In a previous trial of antiretroviral therapy (ART) involving pregnant women with human immunodeficiency virus (HIV) infection, those randomly assigned to receive tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) had infants at greater risk for very premature birth and death within 14 days after delivery than those assigned to receive zidovudine, lamivudine, and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r). METHODS: Using data from two U...
April 26, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29689539/maximizing-the-benefits-of-hiv-preexposure-prophylaxis
#20
Susan P Buchbinder
Preexposure prophylaxis (PrEP) with tenofovir/emtricitabine (slash indicates coformulation) is highly effective in preventing new HIV infections. PrEP efficacy is strongly associated with adherence. In clinical trials, PrEP has been more effective in men who have sex with men and HIV-serodiscordant heterosexual couples than in women, likely reflecting pharmacokinetic differences between levels of tenofovir disoproxil fumarate in vaginal and rectal tissues, and poorer adherence in studies in women. Current guidelines recommend daily PrEP for men and women; however, PrEP taken at least 4 days per week for men may be as effective as daily PrEP, and women must take PrEP 6 to 7 days per week to maximize efficacy...
April 2018: Topics in Antiviral Medicine
keyword
keyword
114588
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"